Nippon Shinyaku and Capricor Therapeutics Enter into Exclusive Partnership for Commercialization and Distribution of Exosome-Secreting Cardiosphere-Derived Cells (CAP-1002) for the Treatment of Duchenne Muscular Dystrophy in US

On January 25, 2022, Nippon Shinyaku Co., Ltd. (Headquarters: Kyoto, Japan, President: Toru Nakai) announced that Nippon Shinyaku and Capricor Therapeutics (Headquarters: California, USA, CEO: Linda Marbán, NASDAQ: CAPR) have entered into an exclusive distribution agreement for CAP-1002 for the treatment of Duchenne muscular dystrophy (DMD) in the territory of the US.

Login Or Register To Read Full Story